VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
TIVC
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
TIVCTivic Health Systems, Inc.
$0.54$2M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. TIVC
  4. Financial Ratios

Tivic Health Systems, Inc. (TIVC) Financial Ratios

Latest Ratios: P/E Ratio -0.1x · EV/EBITDA N/A · ROE -91.8%. (2019–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

TIVC Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Market Cap$2M$416687$1.7B$1M$105M$230M——
Enterprise Value$-4641038$-5774314$1.7B$-1598510$102M$218M——
P/E Ratio →-0.07———————
P/S Ratio4.061.092170.011.2157.19197.61——
P/B Ratio0.010.02667.720.4028.9917.36——
P/FCF————————
P/OCF————————

P/E links to full P/E history page with 30-year chart

TIVC EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
EV / Revenue—-15.122167.45-1.3655.56187.09——
EV / EBITDA————————
EV / EBIT————————
EV / FCF————————

TIVC Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Gross Margin-1.3%-1.3%0.3%24.4%16.3%-11.1%-26.2%-68.8%
Operating Margin-2067.5%-2067.5%-725.8%-701.1%-548.8%-483.0%-372.6%-867.4%
Net Profit Margin-2324.1%-2324.1%-725.0%-701.0%-548.7%-728.5%-423.1%-987.6%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
ROE-91.8%-91.8%-185.0%-228.7%-119.5%-140.5%-609.5%-174.9%
ROA-51.6%-51.6%-142.0%-147.5%-95.9%-102.5%-159.8%-137.2%
ROIC-106.4%-106.4%-781.2%-1033.2%-919.1%-3339.1%—-4553.8%
ROCE-47.2%-47.2%-180.0%-208.8%-112.5%-80.0%-243.9%-153.6%

TIVC Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Debt / Equity0.380.38—0.100.150.05——
Debt / EBITDA————————
Net Debt / Equity—-0.37-0.79-0.85-0.82-0.92—-0.97
Net Debt / EBITDA————————
Debt / FCF————————
Interest Coverage-53.75-53.75———-3.66-7.60-8.36

Net cash position: cash ($13M) exceeds total debt ($6M)

TIVC Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Current Ratio20.1320.139.703.322.5111.721.174.55
Quick Ratio20.1320.138.532.782.0511.370.993.83
Cash Ratio19.5719.577.362.421.8710.640.823.54
Asset Turnover—0.010.280.230.310.080.560.14
Inventory Turnover——2.441.181.793.024.501.49
Days Sales Outstanding—0.9632.2954.0121.2328.8022.0711.30

TIVC Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Dividend Yield————————
Payout Ratio————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Earnings Yield————————
FCF Yield————————
Buyback Yield0.0%0.0%0.0%0.0%0.0%0.0%——
Total Shareholder Yield0.0%0.0%0.0%0.0%0.0%0.0%——
Shares Outstanding—$287370$287M$46650$96730$34933$23032$23000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Capital structure insolvency risk

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Market Valuation Disconnected From Fundamentals

According to recent market data, TIVC trades at a price-to-sales ratio of 4.06, which appears significantly detached from the company's negative gross margins and contracting revenue trajectory, suggesting investors may be pricing the equity as a speculative R&D option rather than a viable commercial enterprise.

The lack of a positive forward P/E or EV/EBITDA multiple reflects the absence of sustainable earnings, forcing the market to rely on book value metrics that are themselves potentially inflated. This valuation premium warrants caution, as it implies an expectation of a strategic pivot or acquisition that remains unproven by current operational output.

Capital Efficiency Remains Deeply Negative

Based on reported figures, TIVC's ROIC has consistently languished in deep negative territory, reaching -26.8% in 2026Q1, which indicates that the company is currently destroying shareholder value with every dollar of capital deployed into its core medical device operations.

The persistent decay in returns on invested capital suggests that the company's cost structure is fundamentally misaligned with its revenue-generating capacity. Without a drastic improvement in margins or a reduction in capital intensity, the company appears unable to achieve the compounding returns necessary to justify its current asset base.

Working Capital Management Shows Instability

As reported in financial statements, the company's cash conversion cycle has exhibited extreme volatility, swinging from 192 days in 2025Q1 to -55 days in 2025Q3, reflecting significant challenges in managing inventory levels and collecting payments from its retail distribution partners.

The erratic nature of the cash conversion cycle suggests that TIVC lacks a predictable operational rhythm, likely exacerbated by the high return rates inherent in its consumer-facing hardware model. Investors should monitor these fluctuations as they indicate potential bottlenecks in the supply chain and a lack of leverage over retail channels.

Debt Burden Escalating Amid Distress

According to recent SEC filings, TIVC's debt-to-equity ratio surged to 1.54 in 2026Q1, marking a significant departure from the near-zero leverage maintained in previous periods and signaling an increased reliance on external financing to sustain its ongoing operational cash burn.

The rapid accumulation of debt in the face of contracting revenue suggests that the company is exhausting its balance sheet flexibility to fund losses. This trend increases the risk of future dilutive equity raises or restrictive covenant triggers, which may further impair shareholder value in the near term.

Misapplication of Traditional Revenue Multiples

The most commonly misapplied metric for TIVC is the price-to-sales ratio, which obscures the company's negative gross margins and fails to account for the fact that each incremental sale may currently be value-destructive rather than value-accretive to the firm's overall financial health.

Analysts should instead focus on unit-level contribution margins and the cash burn rate relative to the remaining liquidity runway. Relying on revenue multiples in a business model where the cost of goods sold exceeds net revenue leads to a dangerous overestimation of the company's intrinsic value.

Download Financial Ratios Data

Includes 30+ ratios · 7 years · Updated daily

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

TIVC — Frequently Asked Questions

Quick answers to the most common questions about buying TIVC stock.

What is Tivic Health Systems, Inc.'s P/E ratio?

Tivic Health Systems, Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.

What is Tivic Health Systems, Inc.'s ROE?

Tivic Health Systems, Inc.'s return on equity (ROE) is -91.8%. The historical average is -156.7%.

Is TIVC stock overvalued?

Based on historical data, Tivic Health Systems, Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are Tivic Health Systems, Inc.'s profit margins?

Tivic Health Systems, Inc. has -1.3% gross margin and -2067.5% operating margin.